AICAR Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What AICAR Does & How It Works

What It Does: Functional Outcomes

• Activates the cell's energy-sensing system (AMPK) without the cell actually running low on fuel, triggering a metabolic state that resembles what exercise produces at the cellular level
• Enhances glucose uptake in skeletal muscle through a mechanism that does not require insulin, relevant to insulin resistance research
• Increases fat burning by removing the brake on the pathway that shuttles fatty acids into mitochondria for oxidation
• Promotes growth of new mitochondria in muscle cells, improving the cell's capacity to produce energy aerobically
• Drives muscle fiber characteristics toward more endurance-oriented, oxidative types
• Stimulates short-term brain cell growth and production of brain-derived neurotrophic factor (BDNF)
• Inhibits the growth and division of cancer cells through two separate mechanisms, one involving energy sensing and one involving disruption of DNA building block production
• Protects heart tissue from ischemia-reperfusion injury in preclinical models

How It Works: Mechanism of Action

AMPK Activation via ZMP Accumulation (Evidence: Animal / In vitro)

AICAR enters cells through adenosine transporters, the same channels that allow adenosine itself to cross cell membranes. Inside the cell, an enzyme called adenosine kinase phosphorylates AICAR into ZMP (AICA ribotide), which accumulates to millimolar concentrations. ZMP is structurally similar to AMP, the low-energy signal that normally activates AMPK, and binds to the regulatory gamma-subunit of the AMPK complex at site 3. This binding promotes phosphorylation of a critical site on the alpha-subunit (threonine-172) by upstream kinase LKB1, fully activating AMPK.

PGC-1alpha Upregulation and Mitochondrial Biogenesis (Evidence: Animal, Narkar et al., 2008)

Activated AMPK drives upregulation of PGC-1alpha, which functions as the master regulator of mitochondrial biogenesis, the process of building new mitochondria. PGC-1alpha activation also increases expression of SIRT1 and SIRT3, both of which regulate broad metabolic gene programs. The result is increased oxidative enzyme activity, induction of slow-twitch oxidative muscle fiber switching, and elevated GLUT4 mRNA levels. In the foundational exercise mimicry study, this cascade produced a muscle phenotype in sedentary mice that resembled trained animals.

Insulin-Independent Glucose Uptake (Evidence: Animal)

AMPK activation drives translocation of GLUT4 glucose transporters from storage vesicles inside the cell to the cell membrane, allowing glucose to enter the cell without requiring insulin signaling. This mechanism bypasses the insulin receptor entirely, the cell absorbs glucose regardless of whether insulin is present or whether the insulin receptor is functioning normally. In insulin-resistant models, this route remains operational when the insulin-mediated route is impaired.

AMPK-Independent Cell Cycle Arrest (Evidence: In vitro / Animal)

A distinct set of AICAR effects operates independently of AMPK activation. ZMP is itself a naturally occurring intermediate in the de novo purine synthesis pathway, the pathway cells use to build the raw materials for DNA replication. ZMP accumulation disrupts this pathway, creating a shortage of purine building blocks that stops rapidly dividing cells from completing cell division. This mechanism produces S-phase arrest in fibroblasts and leukemia cells, and G2/M-phase arrest in glioma cells. Critically, these effects persist even in AMPK-knockout experimental models, confirming their independence from the energy sensing mechanism.

mTOR Pathway Modulation (Evidence: Animal / In vitro)

AMPK activation inhibits mTORC1, the complex that drives protein synthesis and cell growth, while activating mTORC2. Downstream effects include reduced phosphorylation of S6K1 and 4E-BP1, decreased protein synthesis rates, enhanced autophagy (cellular self-cleaning), and cell cycle arrest in rapidly proliferating cells. In EGFR-activated glioblastoma models, this pathway engagement contributed to antiproliferative effects that outperformed rapamycin, with the primary mechanism being suppression of lipid and cholesterol synthesis rather than sole reliance on mTOR inhibition.

AICAR Molecular Profile

Structure reference: View AICAR on PubChem (CID 266934), Publishing team: retrieve 2D structure image from this link.

A note on terminology: AICAR is routinely called a "peptide" in research chemical communities and performance circles. This is technically inaccurate, peptides are chains of amino acids, and AICAR has no amino acid sequence. It is a nucleoside analog derived from purine biosynthesis. The "AICAR peptide" label reflects common usage rather than chemical reality, and this article uses that term where relevant to search intent while clarifying the distinction.

AICAR Uses & Benefits

Exercise Mimicry and Endurance Enhancement

The most widely discussed application of AICAR is its documented ability to produce endurance adaptations in animal models without physical exercise. Researchers target AICAR for its capacity to drive mitochondrial biogenesis, oxidative fiber switching, and enhanced aerobic enzyme activity, adaptations that normally require weeks of training. The mechanism runs through AMPK activation and PGC-1alpha upregulation, producing a muscle phenotype that resembles trained tissue. Evidence comes from animal research only; no human endurance trial data has been published, and WADA banned the compound in 2009 based entirely on the animal findings. (Evidence: Animal, Narkar et al., 2008)

Metabolic Disease and Insulin Resistance

Researchers have studied AICAR extensively in diabetic and metabolically dysfunctional animal models, targeting its ability to drive insulin-independent glucose uptake, suppress hepatic glucose production, and enhance fatty acid oxidation. The insulin-bypass mechanism is particularly relevant to insulin resistance, where the normal insulin-mediated glucose uptake pathway is impaired but the AMPK-mediated GLUT4 translocation route remains functional. Multiple diabetic rodent models, including ob/ob mice, db/db mice, and Zucker Diabetic Fatty rats, showed improved glucose homeostasis with AICAR treatment. Chronic treatment elevated serum triglycerides in some models, indicating the metabolic effects are not uniformly favorable across all lipid parameters. (Evidence: Animal, Moderate)

Skeletal Muscle Aging and Preservation

Age-related muscle decline, sarcopenia, is a research target for AICAR given its effects on mitochondrial biogenesis and oxidative muscle fiber characteristics. The 2025 Wilcox et al. findings demonstrated that chronic AICAR treatment in aged mice reversed age-related changes in skeletal muscle gene expression, reduced markers of muscle atrophy (MAFbx and MuRF1), and improved exercise performance. Separate muscle injury models showed accelerated regeneration in AICAR-treated animals. Researchers studying cachexia, muscle wasting associated with cancer, sepsis, or chronic inflammation, have also explored AICAR given these muscle-preserving mechanisms. The BYU research team explicitly noted that effective doses in mice have not translated to humans. (Evidence: Animal, Wilcox et al., 2025)

Neurogenesis and Brain Function

Short-term AICAR treatment, specifically seven days, increased hippocampal neurogenesis, elevated BDNF levels, and improved cognitive and motor behavioral performance in both young and aged mice. BDNF (brain-derived neurotrophic factor) is the primary growth factor for brain cells and is strongly associated with learning, memory, and protection against neurodegenerative changes. The neurological research carries a critical caveat: benefits were transient, and extending treatment beyond two weeks produced the opposite signal, neuroinflammation and pro-apoptotic gene expression in brain tissue. Actual exercise produces sustained, compounding neurological benefits that AICAR does not replicate with extended use. (Evidence: Animal, Kobilo et al., 2014)

Cancer Cell Biology

AICAR is studied in oncology research for its dual antiproliferative mechanisms, AMPK-mediated mTOR inhibition and AMPK-independent disruption of purine synthesis. In EGFR-activated glioblastoma models, AICAR was more effective than rapamycin at blocking tumor cell growth, with the primary mechanism being inhibition of lipid and cholesterol synthesis. Phase I/II leukemia trials have reported acceptable safety profiles, though efficacy data from those trials is not yet established. The cell cycle arrest effects operate across multiple cancer cell types, including leukemia, glioma, and fibroblast-derived tumor models. This remains an active research area rather than an established therapeutic application. (Evidence: In vitro / Animal / Early-phase human, Preliminary)

Cardiac Ischemia Protection

AICAR was originally developed as acadesine specifically for protecting the heart during and after coronary artery bypass graft (CABG) surgery, targeting ischemia-reperfusion injury, the damage that occurs when blood flow is restored to oxygen-deprived tissue. This application generated the most extensive human data of any AICAR research area. Phase II CABG trials showed acceptable safety and reduced myocardial infarction in a high-risk patient subgroup, though not in the overall population. The RED-CABG trial was halted in 2012 for lack of efficacy across the broader population, not for safety concerns. The cardiac research remains the foundation of what is known about AICAR's human safety profile. (Evidence: Human clinical trial, limited efficacy)

Where This Guide Comes From

AICAR Results & Timelines

Metabolic Effects: Glucose and Insulin Response

• Acute (single dose): Animal research documents improved whole-body insulin action measurable within hours of a single administration; effects on glucose uptake have been documented lasting up to 24 hours from one dose in insulin-resistant rodent models
• Week 1-2: Continuous daily protocols in metabolic disease models showed progressive improvement in glucose homeostasis markers over the first two weeks; hepatic glucose suppression effects are documented within this window
• Week 3-4+: Longer-term protocols in ZDF rats demonstrated sustained metabolic improvement and beta-cell protection; triglyceride elevation appeared as a complicating factor in some extended protocols

Endurance and Muscle Adaptation

• Week 1-2: Oxidative gene expression changes are measurable early in the protocol; mitochondrial biogenesis markers begin increasing within this window in animal models
• Week 3-4: The landmark Narkar et al. study documented the full 44% endurance improvement after four weeks of daily administration in sedentary mice; fiber type transformation toward oxidative characteristics is measurable at this point
• Beyond 4 weeks: Anti-aging muscle research (Wilcox et al., 2025) used chronic administration protocols, suggesting sustained muscle gene expression benefits with continued administration in aged animal models; the duration was not bounded in that study

Neurological Effects

• Week 1: Hippocampal neurogenesis increases and BDNF levels elevated within seven days in both young and aged mice (Kobilo et al., 2014); cognitive and motor improvements were measured at this timepoint
• Week 1-2: Benefits appear to peak during this window based on available animal data
• Beyond 2 weeks: The critical inflection point documented by Guerrieri and van Praag, neuroinflammatory markers and pro-apoptotic gene expression appear in brain tissue beyond this threshold in animal models; the beneficial neurological trajectory reverses

How to Administer AICAR

Subcutaneous Injection (SubQ)

Subcutaneous injection is the primary administration route used in the animal research that produced AICAR's exercise mimicry, muscle aging, and neurogenesis findings. In rodent studies, SubQ injection is used for daily administration protocols, delivering AICAR to systemic circulation for transport to target tissues via adenosine transporters. Common injection sites in research protocols follow standard SubQ conventions. The 1.4-hour plasma half-life measured in human IV studies suggests that SubQ dosing also requires daily administration to maintain relevant biological exposure, though subcutaneous pharmacokinetic data specifically in humans has not been published.

Intramuscular Injection (IM)

Intramuscular administration is not prominently documented in published AICAR research protocols. SubQ is the standard route in animal studies, and IV is the route used in human cardiac surgery trials. IM is not typically described as the preferred route for AICAR research applications, and no bioavailability or onset comparison data between IM and SubQ for this compound has been published.

Intravenous (IV)

IV infusion is the only route with validated human pharmacokinetic and safety data. The cardiac surgery trials used continuous IV infusion at 0.1 mg/kg/min over seven hours, establishing the 1.4-hour plasma half-life measurement and the clean human safety record. IV delivery ensures complete bioavailability and is the route through which all human efficacy and safety data was generated. Outside of controlled clinical or surgical settings, IV administration carries substantially higher practical risk than SubQ.

Oral

Oral administration is not viable for AICAR. Published data places oral bioavailability below 5%, meaning less than one-twentieth of an oral dose reaches systemic circulation. Gastric acid and first-pass hepatic metabolism degrade the compound before it can achieve meaningful plasma concentrations. All research demonstrating AICAR's studied biological effects, metabolic, endurance, neurological, and cardiac, used either SubQ injection or IV infusion. Unlike some compounds where oral forms are in development, no oral formulation of AICAR that addresses this bioavailability barrier has been documented in the published literature.

AICAR Dosage & Cycle Length

Overall dosing range: No validated human dosing protocol exists for metabolic, performance, or muscle preservation applications. The only established human data comes from the cardiac surgery context: IV infusion at 0.1 mg/kg/min delivered continuously over seven hours during CABG procedures. Animal research protocols have used subcutaneous injection, but effective rodent doses have not been shown to translate to humans.

How the goal shifts where you land:

• Animal metabolic research: Single-dose protocols have demonstrated acute effects on insulin action lasting up to 24 hours; chronic multi-week protocols used in metabolic disease models
• Animal endurance research: Four-week daily subcutaneous administration protocols produced the landmark endurance and mitochondrial findings in the Narkar et al. research
• Animal neurological research: Seven-day protocols produced neurogenesis benefits; extended protocols beyond two weeks showed inflammatory and pro-apoptotic changes, flagging a potential upper duration concern (animal data, Preliminary)

Frequency: Daily administration used in most animal research protocols, consistent with the approximately 1.4-hour plasma half-life requiring regular dosing to maintain biologically relevant exposure

Cycle length: Animal protocols range from acute single-dose to multi-week chronic administration; the neurological research specifically flags the two-week mark as an inflection point where effects shifted from beneficial to potentially harmful in rodent brain tissue; no validated human cycle protocol has been established

Loading protocols: Not documented in the published literature for any application

AICAR Vial Sizes, Costs & Quality

Common vial sizes: AICAR is commercially available for research purposes primarily as lyophilized powder. Standard research quantities are typically offered as 50 mg, 100 mg, or 500 mg bulk formats rather than the per-vial sizes common for injectable peptides, reflecting its origin as a laboratory reagent compound rather than a formulated injectable.

Typical cost range: $80-$200 per 100 mg for U.S.-manufactured research-grade AICAR at current market pricing, varies by supplier, quantity, and purity level. Larger bulk quantities reduce the per-milligram cost significantly.

Storage, lyophilized (dry powder):

• Temperature: Requires storage at -20 degrees C
• Shelf life: Stable for extended periods when kept dry and frozen
• Light sensitivity: Protect from light during storage

Storage, reconstituted (in solution):

• Temperature: Requires storage at -20 degrees C, protected from light
• Use window: Reconstituted solution should be used promptly; repeated freeze-thaw cycles reduce compound integrity

Normal appearance after reconstitution: AICAR dissolves in water at 9 mg/mL and typically produces a clear, colorless aqueous solution. The compound has good water solubility, so a properly reconstituted sample should dissolve fully without visible particulates.

Signs of degradation: Visible cloudiness, particulates, yellowing, or any color change in a previously clear solution indicates potential degradation. Degraded compound should not be used.

Quality Considerations

Synthesis purity matters significantly for AICAR, and the compound's history as a laboratory reagent means the research supply chain includes a wide range of quality tiers. The key concern is not just purity of the AICAR itself, but absence of organic solvent residuals, AICAR is frequently handled with DMSO in research settings, and carryover contamination from crude synthesis processes can be present in lower-quality batches. When pricing drops well below market norms, it typically signals shortcuts in the purification stage, which is where the cost of producing a clean compound is concentrated. A certificate of analysis from an independent third-party laboratory, not just a manufacturer's in-house document, is the baseline verification tool for any research-grade AICAR. U.S.-manufactured research compounds come with stricter manufacturing standards, documented chain of custody, and independent testing accountability that overseas sources generally cannot match.

AICAR Side Effects & Safety

Side Effect Spectrum

Contraindications

• Active malignancy or rapidly dividing tissue concern: AICAR's cell cycle arrest properties are documented in cancer models, but the same AMPK-independent antiproliferative mechanisms operate regardless of cell type, rapidly dividing normal cells may be affected
• Compromised purine metabolism: ZMP accumulation disrupts de novo purine synthesis; individuals with conditions involving purine metabolism dysfunction face compounded risk
• Extended use beyond two weeks: Animal neurological research documents a meaningful shift from neurogenic to neuroinflammatory effects at this threshold, this is an animal-model finding, but the signal is specific and replicated
• Insufficient data to confirm safety for performance or metabolic applications in healthy humans outside controlled research settings

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: Insufficient safety data; use is not recommended without medical supervision
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• Cardiovascular conditions: Ion channel effects including Kir2.1 inhibition and RyR1 calcium leak modulation have potential cardiovascular implications that have not been fully characterized outside surgical trial contexts
• Individuals with lipid disorders: Chronic AICAR treatment elevated serum triglycerides in some animal metabolic models, a relevant concern for anyone with existing dyslipidemia
• Cancer patients outside of supervised trials: While AICAR has been studied in leukemia trials with acceptable safety profiles, unsupervised use in active malignancy contexts is not appropriate

Red Flags: Stop Use and Seek Medical Attention If

• Significant unexpected changes in blood lipid markers, particularly triglyceride elevation
• Any neurological symptoms including cognitive changes, mood disturbances, or headache patterns that emerge or worsen during use
• Cardiovascular symptoms including irregular heartbeat, chest discomfort, or unusual palpitations
• Any signs of infection or immune dysregulation, AICAR affects bacterial uptake processes in microglia, and the full immune implications are not well characterized

Drug and Compound Interactions

No formal drug interaction studies for AICAR have been published outside of the cardiac surgery trial context, where concomitant medications were closely monitored without documented interactions. Theoretically, compounds that affect adenosine transporter function could alter AICAR's cellular uptake and intracellular ZMP accumulation. Combinations with other AMPK activators, including metformin, which also activates AMPK through a distinct mechanism, could produce additive or synergistic AMPK activation with unpredictable metabolic consequences. Insulin and insulin sensitizers merit consideration given AICAR's insulin-independent glucose uptake effects. No documented peptide interaction data exists.

AICAR Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability AICAR enters cells via adenosine transporters rather than through a specific receptor-mediated process, making cellular uptake broadly available across tissues that express these transporters. Oral bioavailability is documented at less than 5%, rendering the gastrointestinal route non-viable for achieving meaningful systemic concentrations. All pharmacokinetically relevant administration requires injection.

Distribution AICAR distributes across tissues in proportion to adenosine transporter expression. The research notes preferential AMPK activation in white muscle tissue, though metabolic effects are documented in liver, cardiac tissue, adipose tissue, and brain as well. Intracellular ZMP concentrations reach millimolar levels following uptake, this accumulation is the driving force behind AMPK activation, compensating for ZMP's 40-50-fold lower potency compared to AMP at individual binding events.

Half-Life Plasma half-life following IV administration in humans is approximately 1.4 hours. This measurement comes from the cardiac surgery trial context. Half-life data for subcutaneous administration in humans has not been published, the 1.4-hour figure is the best available reference but may not perfectly characterize SubQ pharmacokinetics.

Metabolism & Elimination Following cellular uptake, adenosine kinase converts AICAR to ZMP. ZMP is itself a natural intermediate in de novo purine biosynthesis, which means its accumulation can disrupt this pathway, a mechanism responsible for some of AICAR's AMPK-independent effects. Elimination routes have not been characterized in detail in published human pharmacokinetic studies.

Mechanistic Research

AMPK Activation and Metabolic Reprogramming (Evidence: Animal / In vitro)

ZMP binds to the gamma-subunit of the AMPK heterotrimeric complex at regulatory site 3, promoting phosphorylation of threonine-172 on the alpha-subunit by upstream kinase LKB1. This fully activates AMPK, initiating broad metabolic reprogramming including GLUT4 translocation, ACC inhibition, and PGC-1alpha upregulation. AMPK knockout models, particularly the alpha-2 isoform, confirm that many downstream metabolic effects require functional AMPK, though the magnitude of effect varies by tissue type and experimental context.

PGC-1alpha Upregulation and Mitochondrial Biogenesis (Evidence: Animal, Narkar et al., 2008)

AMPK activation drives robust upregulation of PGC-1alpha alongside increased expression of SIRT1 and SIRT3. The four-week sedentary mouse protocol demonstrated induction of oxidative fiber switching, enhanced cytochrome c oxidase activity, and increased GLUT4 mRNA levels consistent with a trained muscle phenotype. The study found that combining AICAR with a PPARdelta agonist produced greater adaptations than either compound alone, suggesting the two pathways engage synergistically on the same gene targets.

AMPK-Independent Cell Cycle Arrest (Evidence: In vitro / Animal)

Multiple independent research groups have demonstrated that AICAR's antiproliferative effects in cancer cell lines persist even when AMPK is genetically removed from the model. S-phase arrest in fibroblasts and leukemia cells, and G2/M-phase arrest in glioma cells, appear to be driven by ZMP's disruption of purine biosynthesis rather than through energy sensing. This is mechanistically similar to disruptions observed in Lesch-Nyhan syndrome, a genetic disorder affecting purine metabolism. The finding that these effects predate AMPK discovery in the literature reinforces their independence from the energy sensing pathway.

Neuroinflammation with Extended Treatment (Evidence: Animal, Guerrieri & van Praag, 2015)

A study examining the duration-dependence of AICAR's neurological effects found that benefits documented in the first week of treatment, including increased neurogenesis and BDNF upregulation, did not persist and reversed direction with extended protocols. Treatment beyond two weeks produced upregulation of inflammatory markers and pro-apoptotic gene expression in brain tissue. This contrasted sharply with the sustained neurological benefits of actual physical exercise, which do not show this inflection pattern. The findings establish that AICAR is not an equivalent substitute for exercise from a neurological standpoint.

Condition-Focused Research

Endurance and Exercise Physiology {#research-endurance}

Narkar and colleagues published the foundational exercise mimicry study in Cell in 2008, using four weeks of AICAR treatment in sedentary mice. Running endurance improved by 44% compared to untreated controls, accompanied by induction of oxidative muscle fiber switching, enhanced mitochondrial enzyme activity, and increased oxidative gene expression. The PPARdelta agonist combination produced greater effects than AICAR alone. This study did not demonstrate cardiovascular structural adaptations equivalent to training, the mimicry was primarily metabolic and muscular rather than complete physiological replication. (Evidence: Animal, Narkar et al., 2008)

Skeletal Muscle Aging and Regeneration {#research-muscle}

Wilcox and colleagues published findings in 2025 demonstrating that chronic AICAR treatment in old mice reversed age-related declines in exercise performance and skeletal muscle gene expression. Markers of muscle atrophy, specifically MAFbx and MuRF1, were reduced, mitochondrial enzyme content increased, and treadmill performance improved. Many genes returned to expression levels associated with younger animals. Separately, a muscle injury model showed that AICAR-treated animals had a higher percentage of large muscle fibers six days post-injury, suggesting accelerated regeneration. The researchers noted that future work should focus on human-compatible AMPK activators, since AICAR's effective doses in mice have not translated to humans. (Evidence: Animal, Wilcox et al., 2025)

Metabolic Disease and Diabetes {#research-metabolic}

Multiple animal models, including ob/ob mice, db/db mice, and Zucker Diabetic Fatty rats, demonstrated improvements in glucose homeostasis, whole-body insulin action, and in some protocols, protection of pancreatic beta-cell function. Long-term AICAR administration prevented diabetes in ZDF rats and protected beta-cells from degranulation in published animal research. Chronic treatment in some models elevated serum triglycerides, illustrating that the metabolic effects are not uniformly favorable across all lipid parameters. (Evidence: Animal, Moderate)

Cardiovascular and Cardiac Ischemia {#research-cardio}

The most extensive human trial data for AICAR comes from its original development as acadesine for cardiac surgery protection. A Phase II multicenter randomized controlled trial tested continuous IV infusion during CABG surgery, showing acceptable safety and reduced Q-wave MI in a high-risk patient subgroup, but no benefit in the overall population. The subsequent RED-CABG trial was halted for lack of efficacy; the safety record across both trials remained intact. Preclinical cardiovascular research also documented promotion of endothelium-independent vasorelaxation through AMPK activation and reduced vascular inflammation in atherosclerosis models, though these mechanistic findings did not translate into a clinically meaningful outcome in the surgical trials. (Evidence: Human clinical trial, limited efficacy)

Neurogenesis and Brain Function {#research-neuro}

Kobilo and colleagues demonstrated in 2014 that seven days of AICAR treatment in both young and aged mice increased hippocampal neurogenesis, elevated BDNF levels, and improved performance on cognitive and motor behavioral tests. The short duration was important, subsequent research by Guerrieri and van Praag found that extending treatment beyond two weeks flipped those neurological signals from positive to negative, with inflammatory and pro-apoptotic markers rising in brain tissue. The authors specifically contrasted this with sustained exercise, which produces durable neurological benefits without this reversal. (Evidence: Animal, Kobilo et al., 2014)

Cancer Cell Biology {#research-cancer}

Research demonstrated that AICAR inhibits cancer cell proliferation both in vitro and in vivo through AMPK activation, with subsequent findings showing that in EGFR-activated glioblastoma cells, AICAR outperformed rapamycin at blocking tumor cell growth, with the primary mechanism being inhibition of fatty acid and cholesterol synthesis pathways rather than sole reliance on mTOR inhibition. Phase I/II leukemia trials have reported acceptable safety profiles, though full efficacy data from those trials is not yet established. The cell cycle arrest mechanisms underlying AICAR's antiproliferative effects include both AMPK-dependent and AMPK-independent pathways. (Evidence: In vitro / Animal / Early-phase human, Preliminary)

Safety & Tolerability Research

The clearest human safety data comes from cardiac surgery trials. In the Phase II CABG trial, IV AICAR at 0.1 mg/kg/min over seven hours produced no adverse events. The RED-CABG trial was halted for lack of efficacy in 2012, with safety remaining intact throughout. Phase I/II leukemia trials have also reported acceptable safety profiles. In animal models, the most significant safety signals are elevated serum triglycerides with chronic metabolic dosing, neuroinflammatory and pro-apoptotic changes in brain tissue beyond two weeks, and complex ion channel effects including Kir2.1 inhibition and RyR1 calcium leak modulation. Purine biosynthesis disruption from ZMP accumulation is a consistent mechanistic concern across cell types, with implications analogous to disruptions documented in inherited purine metabolism disorders.

Research Limitations

The central limitation of the AICAR evidence base is the species translation problem. Researchers explicitly noted that AICAR is effective in mice at doses that have not been shown to be potent in humans, this is not a typical pharmaceutical challenge but a specific pharmacokinetic and receptor-density difference between species. The only validated human dosing protocol is the cardiac IV infusion context, which bears no relationship to metabolic or performance applications. No long-term safety data exists in healthy humans for any non-surgical application. The neurological research establishing a two-week inflection point is animal-only and has not been studied in human brain tissue. AICAR's AMPK-independent effects through purine metabolism mean that attributing observed outcomes to AMPK activation alone requires careful experimental controls that are not always present in older studies. Chronic triglyceride elevation in some metabolic models contradicts the otherwise favorable lipid findings, and this inconsistency has not been resolved in the published literature.

Is AICAR Legal? Regulatory & Sports Status

FDA status: No FDA-approved therapeutic indications for AICAR or acadesine. The compound was investigated but not approved for cardiac surgery applications following clinical trial failures. It is classified as a research compound in the United States.

Research Use Only (RUO): In the United States and most major jurisdictions, AICAR is classified as a research compound and is not approved for human therapeutic use. It is commercially available for laboratory research purposes and is sold under research-use-only designations. This classification reflects the absence of regulatory approval rather than a specific prohibition on possession in most jurisdictions, the practical and legal implications of this distinction vary by country.

WADA / USADA status: AICAR is banned under the WADA Prohibited List, classified under metabolic modulators. The prohibition has been in place since 2009, implemented specifically following publication of the Narkar et al. exercise mimicry findings. This is notable because WADA acted on animal data alone, no human performance evidence existed at the time of the ban. The prohibition applies in-competition and out-of-competition.

Country-specific notes: The United Kingdom, Australia, Canada, and European Union member states follow the same general RUO classification without specific approved therapeutic indications. Regulatory status regarding legality of possession varies across jurisdictions; the compound occupies a gray area in most countries where it is neither explicitly illegal to possess nor approved for use. Users outside research settings should verify their local regulatory framework.

Detection: WADA developed detection methods following the 2009 prohibition. The plasma half-life of approximately 1.4 hours makes the parent compound itself a narrow detection window, though metabolite detection may extend the testable period. Athletes have faced sanctions for AICAR use, confirming that detection methods are operational in competitive anti-doping programs.

AICAR vs. Alternatives

Commonly Paired With: Synergistic Stacks

• AICAR + PPARdelta agonists (GW501516 / Cardarine): The Narkar et al. study specifically tested this combination and found greater metabolic and endurance adaptations than either compound alone, the two agents engage overlapping gene targets through complementary pathways. Both are WADA-prohibited and both carry significant unresolved safety questions; the combination documented in animal research has not been evaluated in humans. Stacking information is for educational context, individualized stack protocols live inside MPP.
• AICAR + Metformin: Both compounds activate AMPK, though through distinct mechanisms, AICAR via ZMP accumulation, metformin through mitochondrial complex I inhibition. The theoretical concern is additive or excessive AMPK activation with unpredictable metabolic consequences; no published data on this combination in humans exists.
• AICAR + exercise: Some animal research explored AICAR as a complement to training rather than a substitute, looking at whether AMPK activation on rest days could sustain mitochondrial adaptations. This remains an animal-research context.

Alternatives: When Another Compound May Be Considered

GW501516 (Cardarine) Often compared to AICAR given similar exercise mimicry research and WADA prohibition timelines. GW501516 targets PPARdelta directly rather than AMPK, producing endurance adaptations through a partially overlapping but distinct transcriptional pathway. Critically, GW501516 was abandoned by its developer GlaxoSmithKline after accelerating tumor development across multiple organ systems in animal studies, its safety profile is substantially more concerning than AICAR's. Researchers should weigh the carcinogenesis data carefully before selecting this compound.

Berberine A plant-derived AMPK activator with meaningful oral bioavailability, addressing one of AICAR's primary practical limitations. Berberine activates AMPK through mitochondrial complex I inhibition (similar to metformin) rather than ZMP accumulation, producing metabolic effects with a more established human tolerability record and without WADA-prohibited status. Evidence for metabolic benefits in humans is substantially stronger than for AICAR, though endurance mimicry effects are less pronounced.

Metformin The most clinically established AMPK activator, with decades of human safety and efficacy data in metabolic disease. Metformin lacks the exercise mimicry and mitochondrial biogenesis research profile that makes AICAR interesting for performance research, but for pure metabolic health applications, particularly glucose regulation and insulin sensitivity, its human evidence base is in an entirely different tier than AICAR's.

Comparison table:

Build Your AICAR Protocol

FAQs

What is AICAR?

AICAR (5-Aminoimidazole-4-carboxamide ribonucleoside), also known as acadesine or AICA riboside, is a naturally occurring metabolic intermediate and synthetic nucleoside analog that activates AMPK, the cell's master energy sensor, without requiring actual cellular energy depletion. Despite being widely called "AICAR peptide" in research and performance communities, it is technically a nucleoside analog, not a peptide, as it contains no amino acid sequence. It was originally developed for cardiac surgery protection and has since been studied across metabolic health, exercise physiology, muscle preservation, and cancer biology.

What does AICAR do?

AICAR triggers a cellular state that resembles the metabolic effects of exercise: increased fat burning, enhanced glucose uptake in muscle without requiring insulin, promotion of new mitochondria growth, and a shift toward endurance-oriented muscle fiber characteristics. In animal models, four weeks of AICAR treatment improved running endurance by 44% in sedentary mice. It also inhibits cancer cell proliferation, promotes short-term neurogenesis, and has shown muscle preservation effects in aged animal models.

How long does AICAR take to work?

In animal research, neurological effects, including increased neurogenesis and BDNF levels, appeared within seven days of daily administration. Measurable endurance adaptations developed over four weeks in the landmark exercise mimicry study. Acute metabolic effects on insulin action were documented up to 24 hours after a single dose in animal models. No equivalent human onset timeline data exists for metabolic or performance applications; the only human pharmacokinetic reference is a 1.4-hour plasma half-life measured during cardiac surgery infusion.

What is the typical dose of AICAR?

No validated human dosing protocol exists for metabolic, performance, or muscle preservation applications. The only established human dosing data comes from cardiac surgery trials, where IV infusion at 0.1 mg/kg/min over seven hours was used safely but did not produce efficacy in the overall patient population. Animal research has used subcutaneous injection protocols, but effective rodent doses have not been shown to translate to humans. Individual protocols vary significantly, and there is no community consensus on human dosing comparable to what exists for more established research compounds. MyPeptidePal can help frame protocol context based on available evidence.

Is AICAR legal?

AICAR is classified as a research compound with no approved therapeutic indications in any major jurisdiction, including the United States. It is not explicitly illegal to possess in most countries, but it is not approved for human use. In competitive sports, AICAR has been prohibited by WADA since 2009 under the metabolic modulators category, the prohibition applies both in-competition and out-of-competition, and detection methods are operational. Users are responsible for understanding the regulatory framework in their specific jurisdiction.

Can AICAR be taken orally?

No. Oral bioavailability is documented at less than 5%, meaning nearly all of an oral dose is lost before reaching systemic circulation. Oral administration does not produce meaningful cellular AICAR or ZMP concentrations needed to activate AMPK. All research demonstrating AICAR's studied effects has used either subcutaneous injection or intravenous administration. Unlike some compounds where oral alternatives are in development, there is no documented oral formulation of AICAR that addresses this bioavailability constraint.

Why was AICAR banned by WADA if no human performance data exists?

WADA added AICAR to its prohibited list in 2009 specifically following publication of the Narkar et al. study showing a 44% endurance improvement in sedentary mice, before any human performance research had been conducted. WADA's approach is to prohibit compounds with demonstrated performance-enhancing potential in preclinical research before human evidence accumulates, rather than waiting for athletes to use something, prove it works, and then ban it after the fact. The prohibition is categorized under metabolic modulators on the current prohibited list.

Does AICAR have any approved human uses?

No. AICAR (acadesine) was investigated for FDA approval as a cardiac protection agent during coronary artery bypass surgery but was not approved after Phase II trials showed no benefit in the overall patient population and the RED-CABG trial was halted for lack of efficacy. Phase I/II leukemia trials have reported acceptable safety data, but no approved oncology indication exists. AICAR has no approved therapeutic applications in any major regulatory jurisdiction as of July 2026.

What is the two-week neurological concern with AICAR?

Animal research by Guerrieri and van Praag found that AICAR's beneficial neurological effects, including neurogenesis and BDNF upregulation, documented in the first week of treatment did not persist and reversed direction with extended use. Beyond two weeks, brain tissue in these animal models showed increased inflammatory markers and pro-apoptotic gene expression. This contrasted sharply with physical exercise, which produces sustained and compounding neurological benefits over time. This is a rodent finding that has not been studied in human brain tissue, but it is the most specific duration-related safety signal in AICAR's research record.

What is ZMP and why does it matter?

ZMP is the active intracellular metabolite that AICAR converts into once it enters a cell. Adenosine kinase phosphorylates AICAR into ZMP, which then accumulates to high concentrations inside the cell. ZMP is structurally similar to AMP, the low-energy molecular signal, and binds to the regulatory site on AMPK, activating it without the cell actually running low on energy. ZMP is also a natural intermediate in the purine biosynthesis pathway, which is why its accumulation disrupts that pathway and produces AMPK-independent effects beyond pure energy sensing.

Final Thoughts

AICAR occupies a genuinely unusual position in the research compound landscape. It is the compound most associated with the concept of exercise in a vial, a label that is both scientifically grounded in its mechanism and meaningfully overstated when you look at what the full research record actually shows. The 2008 Cell paper was real, the 44% endurance improvement in sedentary mice was real, and the AMPK activation pathway is among the better-understood signaling mechanisms in metabolic biology. That is not hype, that is the research. What the research also shows is a species translation problem that researchers themselves have flagged explicitly, a less-than-5% oral bioavailability that eliminates the most accessible administration route, neurological research with a documented two-week inflection point, and clinical trial failures in its only human application. AICAR is interesting precisely because both sides of that picture are genuine.

The practical constraints are significant. No validated human protocol exists for metabolic or performance applications. The only human dosing data comes from surgical infusion contexts with no operational relevance outside an operating room. The neurological research suggests that longer use is not better and may be actively worse. And the compound is WADA-prohibited for any competitive athlete. Anyone considering AICAR for research purposes needs to engage with the full evidence picture, the compelling animal data and the hard translation limits simultaneously, not one or the other. Quality sourcing matters for a compound this complex: purity verification through independent certificates of analysis is the baseline, and U.S.-manufactured research-grade AICAR with documented chain of custody reduces meaningful risk in ways that unverified overseas sourcing cannot.

If you are trying to understand where AICAR fits in a broader protocol context, particularly relative to other AMPK activators, endurance compounds, or metabolic health interventions, MyPeptidePal can help map the evidence and the trade-offs against your specific situation and goals. The app does not replace a healthcare professional, and no app should, but it can give you the clearest, most organized picture of what the research shows and where the gaps are, built around your actual health context rather than a generic overview.

References

1. Narkar, V. A., Downes, M., Yu, R. T., Embler, E., Wang, Y. X., Banayo, E., Mihaylova, M. M., Nelson, M. C., Zou, Y., Juguilon, H., Kang, H., Shaw, R. J., & Evans, R. M. (2008). AMPK and PPARdelta agonists are exercise mimetics. Cell, 134(3), 405-415.

2. Wilcox, C. R., Abbott, C. B., Stein, D., & Cornwell, E. W. (2025). Chronic AICAR treatment reverses age-related changes in skeletal muscle gene expression and exercise performance. FASEB BioAdvances, 7(1), 49-60.

3. Kobilo, T., Bhattacharya, T. K., Bhattacharya, S., & van Praag, H. (2014). AICAR and voluntary running increase adult hippocampal neurogenesis and cognition. Learning & Memory, 21(2), 119-126.

4. Guerrieri, D., & van Praag, H. (2015). Exercise-mimetic AICAR transiently benefits brain function. Oncotarget, 6(21), 18293-18313.

5. AICAR - Compound Summary. National Center for Biotechnology Information, PubChem database. CID 266934.